Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Revenue: 2019-2025

Historic Revenue for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $7.9 million.

  • Nurix Therapeutics' Revenue fell 37.29% to $7.9 million in Q3 2025 from the same period last year, while for Aug 2025 it was $83.7 million, marking a year-over-year increase of 48.32%. This contributed to the annual value of $54.5 million for FY2024, which is 29.15% down from last year.
  • Nurix Therapeutics' Revenue amounted to $7.9 million in Q3 2025, which was down 82.08% from $44.1 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Revenue ranged from a high of $44.1 million in Q2 2025 and a low of $5.0 million during Q1 2021.
  • Moreover, its 3-year median value for Revenue was $15.2 million (2023), whereas its average is $18.4 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Revenue crashed by 60.58% in 2024, and later soared by 264.34% in 2025.
  • Nurix Therapeutics' Revenue (Quarterly) stood at $7.4 million in 2021, then fell by 8.29% to $6.8 million in 2022, then soared by 123.49% to $15.2 million in 2023, then dropped by 12.37% to $13.3 million in 2024, then plummeted by 37.29% to $7.9 million in 2025.
  • Its Revenue was $7.9 million in Q3 2025, compared to $44.1 million in Q2 2025 and $18.5 million in Q1 2025.